Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus for Children With Refractory or Recurrent Low-Grade Gliomas
NCT00782626Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jun 2009
- Primary completion
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus in glioma, sponsored by Dana-Farber Cancer Institute. Primary endpoint: Overall Response at 48 weeks. Started Jun 2009; status: completed.
02
Drugs
everolimus
03
Conditions
glioma
Beyond the preview
Go deeper on NCT00782626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00782626.